|
Quinapril
resources
|
|
|
|
|
|
DRUG INFO Quinapril
Drug Name:
Quinapril
Indication: For the treatment of hypertension and chronic heart failure
Pharmacology: Quinapril, an angiotensin-converting enzyme (ACE) inhibitor, is used to treat hypertension and heart failure. Like ramipril, quinapril is a prodrug that, upon deesterification, is converted to the active metabolite quinaprilat. The effect of quinapril in hypertension and in congestive heart failure (CHF) appears to result primarily from the inhibition of circulating and tissue ACE activity, thereby reducing angiotensin II formation.
Mechanism Of Action: Quinaprilat competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms. Quinaprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin.
Drug Category: Antihypertensive Agents; Angiotensin-converting Enzyme Inhibitors; ATC:C09AA06
Brand Names/Synonyms: Accupril; Accuprin; Accupro; Acequin; Acuitel; Korec; Quinapril; Quinapril Hcl; Quinapril Hydrochloride; Quinapril Hydrochloride: Accupril; Quinaprilum [Latin]; Quinazil
Dosage Forms: Tablets
Absorption: Following oral administration, peak plasma quinapril concentrations are observed within one hour. Based on recovery of quinapril and its metabolites in urine, the extent of absorption is at least 60%. The rate and extent of quinapril absorption are diminished moderately (approximately 25-30%) when ACCUPRIL tablets are administered during a high-fat meal.
Interactions:
DrugBank: Interactions for Quinapril
Interactions for Quinapril:
Concomitant diuretic therapy
As with other ACE inhibitors, patients on diuretics, especially those on recently instituted diuretic
therapy, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with
ACCUPRIL. The possibility of hypotensive effects with ACCUPRIL may be minimized by either discontinuing the diuretic
or cautiously increasing salt intake prior to initiation of treatment with ACCUPRIL. If it is not possible to
discontinue the diuretic, the starting dose of quinapril should be reduced.
Agents increasing serum potassium
Quinapril can attenuate potassium loss caused by thiazide diuretics and increase serum potassium when
used alone. If concomitant therapy of ACCUPRIL with potassium-sparing diuretics (eg, spironolactone, triamterene, or
amiloride), potassium supplements, or potassium-containing salt substitutes is indicated, they should be used with
caution along with appropriate monitoring of serum potassium.
Tetracycline and other drugs that interact with magnesium
Simultaneous administration of tetracycline with ACCUPRIL reduced the absorption of tetracycline by
approximately 28% to 37%, possibly due to the high magnesium content in ACCUPRIL tablets. This interaction should be
considered if coprescribing ACCUPRIL and tetracycline or other drugs that interact with magnesium.
Lithium
Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients
receiving concomitant lithium and ACE inhibitor therapy. These drugs should be coadministered with caution and
frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, it may increase the risk of
lithium toxicity.
Other agents
Drug interaction studies of ACCUPRIL with other agents showed:
· Multiple dose therapy with propranolol or cimetidine has no
effect on the pharmacokinetics of single doses of ACCUPRIL.
· The anticoagulant effect of a single dose of warfarin (measured
by prothrombin time) was not significantly changed by quinapril coadministration twice-daily.
· ACCUPRIL treatment did not affect the pharmacokinetics of digoxin.
· No pharmacokinetic interaction was observed when single doses of
ACCUPRIL and hydrochlorothiazide were administered concomitantly.
· Co-administration of multiple 10 mg doses of atorvastatin with
80 mg of ACCUPRIL resulted in no significant change in the steady-state pharmacokinetic parameters of
atorvastatin.
Chemical IUPAC Name: 2-[2-(1-ethoxycarbonyl-3-phenyl-propyl)aminopropanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
Chemical Formula: C25H30N2O5
Half Life: 2 hours
Drug Type: Approved Drug
# Accession No: APRD00523
CAS Registry Number: 85441-61-8
|
|
|
|
|
|
Quinapril News (When available)
Irreparable Harm Presumed on Strong Showing of Likely Infringement Jan 5, 2006 Mondaq News Alerts, Accupril is an angiotensin converting enzyme (ACE) inhibitor composed of the active ingredient quinapril and is used to treat hypertension or high blood ...
Heart drug use has increased, but still suboptimal Jan 9, 2006 Reuters.uk, In 2002, rates of overall and consistent use of angiotensin-converting enzyme (ACE) inhibitors, such as Accupril and Vasotec, in patients with heart failure ...
Heart patients don't stick to drug programs Jan 10, 2006 News-Medical.net, In 2002, rates of overall and consistent use of ACE inhibitors, such as Accupril and Vasotec, in patients with heart failure were 51 percent and 39 percent ...
DemiDose(TM) Pill Splitter Allays Concern Over Dose Accuracy in ... Jan 11, 2006 PR Newswire (press release), ...medications on the market today, including: Thyroid Heart - Blood Pressure Erectile Dysfunction Cholesterol - Synthroid - Accupril - Viagra - Lipitor - Norvasc ...
Intellectual Property Federal Circuit Alert Dec 19, 2005 Mondaq News Alerts, The Warner-Lambert Company, LLC owns the '450 Patent and markets the resulting ACE inhibitor formulation as Accupril®. On January ...
Taking Charge Smith steps forward with 19 points as Trinity beats ... Jan 11, 2006 Stamford Advocate, ...just three field goals by Ben Lazerus. Dejan Korec had nine points and eight rebounds for Trinity. Stamford (4-4, 2-4), which suffered ...
|
|
|